<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ABSTRACT: The risk of cardiovascular complication in a <z:mp ids='MP_0002055'>diabetes</z:mp> patient is similar to that in a nondiabetic patient with a history of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although intensive control of glycemia achieved by conventional <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents decreases microvascular complications such as <z:hpo ids='HP_0000488'>retinopathy</z:hpo> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, no marked effect has been reported on macrovascular complications or <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="2" pm="."><plain>Evidence from VADT, ACCORD, and ADVANCE would suggest that glycemic control has little effect on macrovascular outcomes </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, in the case of ACCORD, intensive glycemic control may be associated with an increased risk of mortality </plain></SENT>
<SENT sid="4" pm="."><plain>There is sufficient evidence that suggests that <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> may be an independent risk factor for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
<SENT sid="5" pm="."><plain>However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> leads to lower risk of cardiovascular outcomes </plain></SENT>
<SENT sid="6" pm="."><plain>Mitiglinide is a short-acting insulinotropic agent used in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> treatment </plain></SENT>
<SENT sid="7" pm="."><plain>It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> level in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Because of its short action time, it is unlikely to exert adverse effects related to <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> early in the morning and between meals </plain></SENT>
<SENT sid="9" pm="."><plain>Mitiglinide reduces excess <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mp ids='MP_0001845'>inflammation</z:mp>, plays a cardioprotective role, and improves postprandial <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, mitiglinide add-on therapy with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> favorably affects the vascular endothelial function in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
<SENT sid="11" pm="."><plain>These data suggest that mitiglinide plays a potentially beneficial role in the improvement of <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients and can be used to prevent <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Although the results of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic </plain></SENT>
</text></document>